ArticleHeadache

Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias.

Marta Vila-Pueyo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.